Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain

Journal of Pain Research

Volumn 4, Issue , 2011, Pages 111-125

  Ferrari, Flora ^a   Fiorentino, Simonetta ^a   Mennuni, Laura ^a   Garofalo, Paolo ^a   Letari, Ornella ^a   Mandelli, Stefano ^a   Giordani, Antonio ^a   Lanza, Marco ^a   Caselli, Gianfranco ^a  

^a Rotta Research Laboratorium   (Italy)

Author keywords

Allodynia; CR4056; Hyperalgesia; Imidazoline 2 receptors; Inflammatory pain; Neuropathic pain

Indexed keywords

EID: 80755138119     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S18353     Document Type: Article

References (46)

1. Molderings GJ. Imidazoline receptors: basic knowledge, recent advances, and future prospects for therapy and diagnosis. Drug Future. 1997;22:757-772.
2. Piletz JE, Ivanov TR, Sharp JD, et al. Imidazoline receptor antiseraselected (IRAS) cDNA: cloning and characterization. DNA Cell Biol. 2000;19:319-329.
3. Bousquet P. Identification and characterization of I1 imidazoline receptors: their role in blood pressure regulation. Am J Hypertens. 2000;13:84S-88S.
4. Tesson F, Limon-Boulez I, Urban P, et al. Localization of I2-imidazoline binding sites on monoamine oxidases. J Biol Chem. 1995;270: 9856-9861.
5. Carpéné C, Collon P, Remaury A, et al. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites. J Pharmacol Exp Ther. 1995;272:681-688.
6. Ozaita A, Olmos G, Boronat MA, Lizcano JM, Unzeta M, García-Sevilla JA. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver. Br J Pharmacol. 1997;121:901-912.
7. McDonald GR, Olivieri A, Ramsay RR, Holt A. On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B. Pharmacol Res. 2010;62(6):475-488.
8. Kimura A, Tyacke RJ, Robinson JJ, et al. Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site. Brain Res. 2009;1279:21-28.
9. Holt A, Smith DJ, Cendron L, Zanotti G, Rigo A, Di Paolo ML. Multiple binding sites for substrates and modulators of semicarbazidesensitive amine oxidases: kinetic consequences. Mol Pharmacol. 2008; 73:525-538.
10. García-Sevilla JA, Escribá PV, Sastre M, et al. Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims. Arch Gen Psychiatry. 1996;53:803-810.
11. García-Sevilla JA, Escribá PV, Walzer C, Bouras C, Guimón J. Imidazoline receptor proteins in brains of patients with Alzheimer's disease. Neurosci Lett. 1998;247:95-98.
12. Piletz JE, Zhu H, Ordway G, et al. Imidazoline receptor proteins are decreased in the hippocampus of individuals with major depression. Biol Psychiatry. 2000;48:910-919.
13. Boronat MA, Olmos G, García-Sevilla JA. Attenuation of tolerance to opioid-induced antinociception and protection against morphineinduced decrease of neurofilament proteins by idazoxan and other I2-imidazoline ligands. Br J Pharmacol. 1998;125:175-185.
14. Fairbanks CA, Schreiber KL, Brewer KL, et al. Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci. 2000;97:10584-10589.
15. Aricioglu F, Korcegez E, Bozkurt A, Ozyalcin S. Effect of agmatine on acute and mononeuropathic pain. Ann N Y Acad Sci. 2003; 1009:106-115.
16. Gentili F, Cardinaletti C, Carrieri A, et al. Involvement of I2-imidazoline binding sites in positive and negative morphine analgesia modulatory effects. Eur J Pharmacol. 2006;553:73-81.
17. Wu N, Su RB, Li J. Agmatine and imidazoline receptors: their role in opioid analgesia, tolerance and dependence. Cell Mol Neurobiol. 2008; 28:629-641.
18. Ruiz-Durantez E, Torrecilla M, Pineda J, Ugedo L. Attenuation of acute and chronic effects of morphine by the imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline in rat locus coeruleus neurons. Br J Pharmacol. 2003;138:494-500.
19. Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med. 2010; doi: 10.1177/0269216310378546.
20. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573-581.
21. 3H]Ro 19-6327: a reversible ligand and affinity labelling probe for monoamine oxidase-B. Eur J Pharmacol. 1989;162:457-465.
22. 3H]Ro 41-1049 to active site of human monoamine oxidase-A. Mol Pharmacol. 1990;37:358-366.
23. Kim SH, Song J, Mun H, Park KU. Effect of the combined use of tramadol and milnacipran on pain threshold in an animal model of fibromyalgia. Korean J Intern Med. 2009;24:139-142.
24. Nielsen AN, Mathiesen C, Blackburn-Munro G. Pharmacological characterisation of acid-induced muscle allodynia in rats. Eur J Pharmacol. 2004;487:93-103.
25. Hwang SL, Liu IM, Tzeng TF, Cheng JT. Activation of imidazoline receptors in adrenal gland to lower plasma glucose in streptozotocininduced diabetic rats. Diabetologia. 2005;48:767-775.
26. Chang CH, Wu HT, Cheng KC, Lin HJ, Cheng JT. Increase of beta-endorphin secretion by agmatine is induced by activation of imidazoline I(2A) receptors in adrenal gland of rats. Neurosci Lett. 2010;468:297-299.
27. Ruiz-Durántez E, Ruiz-Ortega JA, Pineda J, Ugedo L. Effect of agmatine on locus coeruleus neuron activity: possible involvement of nitric oxide. Br J Pharmacol. 2002;135:1152-1158.
28. Rawls SM, Tallarida RJ, Zisk J. Agmatine and a cannabinoid agonist, WIN 55212-2, interact to produce a hypothermic synergy. Eur J Pharmacol. 2006;553:89-98.
29. Aggarwal S, Shavalian B, Kim E, Rawls SM. Agmatine enhances cannabinoid action in the hot-plate assay of thermal nociception. Pharmacol Biochem Behav. 2009;93:426-432.
30. 3H]2-BFI binding to brain imidazoline I2 sites. Eur J Pharmacol. 2001;428:221-225.
31. Jasmin L, Tien D, Janni G, Ohara PT. Is noradrenaline a significant factor in the analgesic effect of antidepressants? Pain. 2003;106:3-8.
32. Pertovaara A. Noradrenergic pain modulation. Prog Neurobiol. 2006;80:53-83.
33. Finnerup NB. A review of central neuropathic pain states. Curr Opin Anaesthesiol. 2008;21:586-589.
34. Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics. 2009;6:703-712.
35. Ossipov MH, Lai J, Malan TP, Porreca F. Spinal and supraspinal mechanisms of neuropathic pain. Ann N Y Acad Sci. 2000;909:12-24.
36. Dubner R. The neurobiology of persistent pain and its clinical implications. Suppl Clin Neurophysiol. 2004;57:3-7.
37. Brightwell JJ, Taylor BK. Noradrenergic neurons in the locus coeruleus contribute to neuropathic pain. Neuroscience. 2009;160:174-185.
38. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237-251.
39. Marks DM, Shah MJ, Patkar AA, Masand PS, Park G-Y, Pae C-U. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. Curr Neuropharmacol. 2009;7:331-336.
40. Dina OA, Khasar SG, Alessandri-Haber N, et al. Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy. Eur J Neurosci. 2008;28:1180-1190.
41. Napier LD, Stanfill A, Yoshishige DA, Jackson KE, Barron BA, Caffrey JL. Autonomic control of heart rate in dogs treated chronically with morphine. Am J Physiol. 1998;275:H2199-H2210.
42. McCrimmon DR, Alheid GF. On the opiate trail of respiratory depression. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1274-R1275.
43. Klein-Schwartz W. Trends and toxic effects from pediatric clonidine exposures. Arch Pediatr Adolesc Med. 2002;156:392-396.
44. Sweetman S, editor. Martindale: The Complete Drug Reference, 36th ed. London: Pharmaceutical Press; 2009.
45. Olmos G, Alemany R, García-Sevilla JA. Pharmacological and molecular discrimination of brain I2-imidazoline receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 1996;354:709-716.
46. Schlatter E, Ankorina-Stark I, Haxelmans S, Hohage H. Moxonidine inhibits Nai/H//exchange in proximal tubule cells and cortical collecting duct. Kidney Int. 1997;52:454-459.